In vitro to clinical efficacy: Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 strains.
Kakimoto M, Nomura T, Nazmul T, Yamamoto A, Ikeda K, Miyamori D, Higashiura A, Kaiki Y, Kitagawa H, Omori K, Shigemoto N, Ito M, Sakaguchi T, Ohge H.
Kakimoto M, et al. Among authors: ikeda k.
J Infect Chemother. 2024 Dec 30:102604. doi: 10.1016/j.jiac.2024.102604. Online ahead of print.
J Infect Chemother. 2024.
PMID: 39743178